1. Neuro Cell PD, the Parkinson's drug will be in phase 3 during 2000 and has been put on the fast track by the FDA. 2. They've got 22MM with a 500-700K/month burn rate.( I was mistaken in my last post.)3. A Market Cap of only 100MM. That's small, and leaves a pretty large upside.4. Paine Weber just started tracking them and no other analysts are listed on Yahoo. This tells me they are still beneath the radar of the big Wall Street firms.
I've followed Diacrin closely for several years. They always seemed like a very cool company.The news on The parkinsons trial data announced in qtr 3 could be huge ,but the stock could have an extreme reaction to this news. It will be very interesting to watch this play out.
Best Of |
Favorites & Replies |
Start a New Board |
My Fool |